Stay updated on Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed study information regarding the efficacy and safety of a treatment for advanced melanoma, while adding a new version identifier and collaborators.SummaryDifference11%
- Check31 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 7, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.5%
- Check38 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check89 days agoChange DetectedThe page has updated the number of study locations from 37 to 41 and added specific locations in Georgia, Ohio, Germany, and Spain. Additionally, there are new dates related to the study's timeline.SummaryDifference5%
Stay in the know with updates to Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page.